Results 1 to 10 of about 12,098 (189)

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion [PDF]

Frontiers in Oncology, 2023
C-ros oncogene 1 (ROS1) fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC ...
Yun Shu, Zhouyu Wang, Zhouyu Wang, Hongjuan Shang, Wei Le, Yan Lei, Yan Lei, Longzhang Huang, Liming Tao, Jun Chen, Jing Li, Jing Li   +11 more
doaj   +2 more sources

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report [PDF]

Frontiers in Pharmacology, 2022
Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations.
Ningning Yan, Siyuan Huang, Linlin Li, Qianqian Guo, Di Geng, Huixian Zhang, Sanxing Guo, Xingya Li   +7 more
doaj   +2 more sources

Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib [PDF]

Frontiers in Pharmacology
BackgroundSmall cell lung cancer (SCLC) is characterized by an exceedingly low mutation rate in oncogenic driver alterations, and there are currently no articles or case reports documenting SCLC patients carrying ROS1 fusions. Tyrosine kinase inhibitors (
Mengli Qiu, Mengli Qiu, Peiwen Guo, Peiwen Guo, Sisi Wang, Yong Zhu, Yong Zhu, Siqi Wu, Siqi Wu, Huiting Peng, Huiting Peng, Zehuai Guo, Yanmeng Guo, Jieheng Lin, Yang Cao   +14 more
doaj   +2 more sources

Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib [PDF]

Frontiers in Oncology
The incidence of the ROS1 fusion mutation (ROS proto-oncogene 1) in non-small cell lung cancer (NSCLC) is approximately 1-2%. At least 55 partner genes have been identified that can fuse with ROS1.Herein, we report a case of a lung adenocarcinoma patient
Yifan Yang, Yifan Yang, Qing Yi, Wei Yang, Yongzhong Luo, Lemeng Zhang   +5 more
doaj   +2 more sources

Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report [PDF]

Respiratory Medicine Case Reports
For patients with advanced non-small cell lung cancer (NSCLC), genetic testing is crucial to identify alterations in targetable driver genes. ROS1-tyrosine kinase inhibitors have shown efficacy against NSCLC with common ROS1 fusion genes, but the impact ...
Yasuyuki Kishikawa, Kohei Otsubo, Daisuke Shibahara, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto   +6 more
doaj   +2 more sources

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib [PDF]

Thoracic Cancer, 2021
ROS1 rearrangements are found in 1–2% of patients with non‐small‐cell lung cancer. The detection of the rearrangements is crucial since clinically effective molecular targeted drugs are available for them.
Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima, Tetsuya Shiomi   +10 more
doaj   +2 more sources

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report [PDF]

Case Reports in Oncology, 2023
Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ...
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto   +12 more
doaj   +2 more sources

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report [PDF]

Case Reports in Oncology, 2022
ROS1 comprises a small molecular subset of NSCLC, and several fusion partners have been discovered. Concomitant mutations of EGFR and ROS1 in NSCLC have been occasionally reported, while no clear standard of treatment has been revealed.
Sicai Zhang, Zhiyong Xu, Weimin Zhang
doaj   +2 more sources

Different effects of crizotinib treatment in two non‐small cell lung cancer patients with SDC4::ROS1 fusion variants [PDF]

Thoracic Cancer
The possibility of stratifying patients according to differences in ROS proto‐oncogene 1 (ROS1) fusion partners has been discussed. This study aimed to clarify the clinicopathological differences between two SDC4::ROS1 positive NSCLC cases who had ...
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki‐Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda   +16 more
doaj   +2 more sources

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC [PDF]

JTO Clinical and Research Reports, 2022
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow ...
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD   +19 more
doaj   +2 more sources